![Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double- blind, placebo-controlled, phase 2 trial - The Lancet Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double- blind, placebo-controlled, phase 2 trial - The Lancet](https://www.thelancet.com/cms/asset/3acbeff3-54b8-4edb-beeb-0d9aafb29061/gr1.jpg)
Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double- blind, placebo-controlled, phase 2 trial - The Lancet
The double-blind gaze: how the double-blind experimental protocol changed science - Document - Gale Academic OneFile
![Pfizer Inc. on X: "See our latest double-blind #RA trial in @TheLancet https://t.co/epRS9CLJnX https://t.co/9Rqt84hZy0" / X Pfizer Inc. on X: "See our latest double-blind #RA trial in @TheLancet https://t.co/epRS9CLJnX https://t.co/9Rqt84hZy0" / X](https://pbs.twimg.com/media/DCbmQQSUwAAI6eR.jpg)